Longitudinal tumour biopsies collected during FGFR inhibitor trials will ultimately clarify which phospho signatures predict response and whether secondary mutations in FGFR2 or its downstream effectors emerge under therapeutic pressure [50]. This evidence concerns the gene FGFR2 and neoplasm.